Christoph Salat
Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy.
Huober J, van Mackelenbergh M, Schneeweiss A, Seither F, Blohmer J, Denkert C, Tesch H, Hanusch C, Salat C, Rhiem K, Solbach C, Fasching P, Jackisch C, Reinisch M, Lederer B, Mehta K, Link T, Nekljudova V, Loibl S, Untch M. Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy. NPJ Breast Cancer 2023; 9:23.
07.04.2023Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy.
07.04.2023NPJ Breast Cancer 2023; 9:23
Huober Jens, van Mackelenbergh Marion T, Schneeweiss Andreas, Seither Fenja, Blohmer Jens-Uwe, Denkert Carsten, Tesch Hans, Hanusch Claus, Salat Christoph, Rhiem Kerstin, Solbach Christine, Fasching Peter Andreas, Jackisch Christian, Reinisch Mattea, Lederer Bianca, Mehta Keyur M, Link Theresa, Nekljudova Valentina, Loibl Sibylle, Untch Michael
Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy
Furlanetto J, Lederer B, Gerber B, Zahm D, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Couch F, Schmutzler R, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer J, Lübbe K, Untch M, Salat C, Huober J, Klare P, Fasching P. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2021; 145:44-52.
07.01.2021Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy
07.01.2021Eur J Cancer 2021; 145:44-52
Furlanetto Jenny, Lederer Bianca, Gerber Bernd, Zahm Dirk-Michael, Bauerfeind Ingo, Nekljudova Valentina, Hanusch Claus, Jackisch Christian, Link Theresa, Hahnen Eric, Loibl Sibylle, Couch Fergus J, Schmutzler Rita, Möbus Volker, Schneeweiss Andreas, Rhiem Kerstin, Tesch Hans, Blohmer Jens-Uwe, Lübbe Kristina, Untch Michael, Salat Christoph, Huober Jens, Klare Peter, Fasching Peter A
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
Laakmann E, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Nekljudova V, Müller V, Blohmer J, Zahm D, Witzel I, Fasching P, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Salat C, Loibl S. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Res 2019; 21:60.
10.05.2019Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
10.05.2019Breast Cancer Res 2019; 21:60
Laakmann Elena, Ingold-Heppner Barbara, Huober Jens, Hanusch Claus, Jackisch Christian, Reinisch Mattea, Untch Michael, von Minckwitz Gunter, Nekljudova Valentina, Müller Volkmar, Blohmer Jens-Uwe, Zahm Dirk-Michael, Witzel Isabell, Fasching Peter A, Rezai Mahdi, Schem Christian, Solbach Christine, Tesch Hans, Klare Peter, Schneeweiss Andreas, Salat Christoph, Loibl Sibylle
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
von Minckwitz G, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching P, Sinn B, Engels K, Mehta K, Nekljudova V, Klare P, Eidtmann H, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer J, Jackisch C, Paepke S, Gerber B, Zahm D, Kümmel S, Untch M. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15:747-56.
30.04.2014Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
30.04.2014Lancet Oncol 2014; 15:747-56
von Minckwitz Gunter, Huober Jens, Costa Serban, Tesch Hans, Hanusch Claus, Hilfrich Jörn, Khandan Fariba, Fasching Peter A, Sinn Bruno V, Engels Knut, Mehta Keyur, Nekljudova Valentina, Klare Peter, Eidtmann Holger, Schneeweiss Andreas, Loibl Sibylle, Salat Christoph, Denkert Carsten, Rezai Mahdi, Blohmer Jens U, Jackisch Christian, Paepke Stefan, Gerber Bernd, Zahm Dirk M, Kümmel Sherko, Untch Michael